{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:04:44Z","timestamp":1790665484738,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s11864-021-00862-z","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T12:10:14Z","timestamp":1623327014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia"],"prefix":"10.1007","volume":"22","author":[{"given":"Guilherme Fleury","family":"Perini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Cristina Pellegrino","family":"Feres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Lane Cardoso","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-5310","authenticated-orcid":false,"given":"Nelson","family":"Hamerschlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"issue":"5","key":"862_CR1","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1056\/nejmra1908213","volume":"383","author":"JA Burger","year":"2020","unstructured":"Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med. 2020;383(5):460\u201373. https:\/\/doi.org\/10.1056\/nejmra1908213.","journal-title":"N Engl J Med"},{"key":"862_CR2","doi-asserted-by":"publisher","unstructured":"International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779\u201390. https:\/\/doi.org\/10.1016\/s1470-2045(16)30029-8. Describes the importance of citogenetic markers in CLL treatment decision.","DOI":"10.1016\/s1470-2045(16)30029-8"},{"issue":"2","key":"862_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood.2018882555","volume":"134","author":"AW Roberts","year":"2019","unstructured":"Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019;134(2):111\u201322. https:\/\/doi.org\/10.1182\/blood.2018882555.","journal-title":"Blood."},{"key":"862_CR4","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/nejmoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517\u201328. https:\/\/doi.org\/10.1056\/nejmoa1812836.","journal-title":"N Engl J Med"},{"issue":"14","key":"862_CR5","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2217\/fon-2017-0031","volume":"13","author":"J Crombie","year":"2017","unstructured":"Crombie J, Davids MS. Venetoclax for the treatment of patients with chronic lymphocytic leukemia. Future Oncol. 2017;13(14):1223\u201332. https:\/\/doi.org\/10.2217\/fon-2017-0031.","journal-title":"Future Oncol"},{"key":"862_CR6","doi-asserted-by":"publisher","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline, et al. Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1713976. Phase 3 trial of anti CD20 and venetoclax demonstrated a better disease control and durable responses comparing to chemo immunotherapy in pre treated CLL patients.","DOI":"10.1056\/NEJMoa1713976"},{"key":"862_CR7","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1815281.","journal-title":"N Engl J Med"},{"issue":"9","key":"862_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrc883","volume":"2","author":"S Cory","year":"2002","unstructured":"Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647\u201356. https:\/\/doi.org\/10.1038\/nrc883.","journal-title":"Nat Rev Cancer"},{"issue":"7042","key":"862_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677\u201381. https:\/\/doi.org\/10.1038\/nature03579.","journal-title":"Nature."},{"issue":"16","key":"862_CR10","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/sj.onc.1210028","volume":"26","author":"D Chauhan","year":"2007","unstructured":"Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, et al. Novel Bcl-2\/Bcl-X(L)\/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007;26(16):2374\u201380. https:\/\/doi.org\/10.1038\/sj.onc.1210028.","journal-title":"Oncogene."},{"issue":"5","key":"862_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","volume":"10","author":"M Konopleva","year":"2006","unstructured":"Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375\u201388. https:\/\/doi.org\/10.1016\/j.ccr.2006.10.006.","journal-title":"Cancer Cell"},{"issue":"5","key":"862_CR12","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/jco.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488\u201396. https:\/\/doi.org\/10.1200\/jco.2011.34.7898.","journal-title":"J Clin Oncol"},{"key":"862_CR13","doi-asserted-by":"publisher","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311\u201322. https:\/\/doi.org\/10.1056\/nejmoa1513257. First-in-human, phase I dose escalation study to establish venetoclax as a well-tolerated, efficacious treatment for patients with relapsed\/refractory CLL.","DOI":"10.1056\/nejmoa1513257"},{"issue":"1","key":"862_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","volume":"11","author":"GF Perini","year":"2018","unstructured":"Perini GF, Ribeiro GN, Pinto Neto JV, Campos LT, Hamerschlak N. BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol. 2018;11(1):65. https:\/\/doi.org\/10.1186\/s13045-018-0608-2.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"862_CR15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333. https:\/\/doi.org\/10.1200\/JCO.2016.70.4320.","journal-title":"J Clin Oncol"},{"issue":"4","key":"862_CR16","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bcp.13175","volume":"83","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, et al. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol. 2017;83(4):846\u201354. https:\/\/doi.org\/10.1111\/bcp.13175.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"862_CR17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/jcph.730","volume":"56","author":"SK Agarwal","year":"2016","unstructured":"Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of rifampin\u2019s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study. J Clin Pharmacol. 2016;56(11):1335\u201343. https:\/\/doi.org\/10.1002\/jcph.730.","journal-title":"J Clin Pharmacol"},{"key":"862_CR18","doi-asserted-by":"publisher","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, Phase 2 study. Lancet Oncol. 2016;17(6):768\u201378. https:\/\/doi.org\/10.1016\/s1470-2045(17)30012-8. This phase II study showed that venetoclax is highly efficacious in patients with high-risk CLL with del(17p).","DOI":"10.1016\/s1470-2045(17)30012-8"},{"key":"862_CR19","unstructured":"Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18(2):230\u201340. First trial with venetoclax plus rituximab; results showed a deep response with durable disease control."},{"key":"862_CR20","doi-asserted-by":"publisher","unstructured":"Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D\u2019Rozario J, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020:JCO.20.00948. https:\/\/doi.org\/10.1200\/jco.20.00948.","DOI":"10.1200\/jco.20.00948"},{"issue":"9","key":"862_CR21","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/s1470-2045(20)30443-5","volume":"21","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink A-M, Robrecht S, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. 2020;21(9):1188\u2013200. https:\/\/doi.org\/10.1016\/s1470-2045(20)30443-5.","journal-title":"The Lancet Oncology"},{"issue":"5","key":"862_CR22","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bjh.13403","volume":"169","author":"GL Jones","year":"2015","unstructured":"Jones GL, Will A, Jackson GH, Webb NJ. Rule S; British Committee for Standards in Haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015;169(5):661\u201371. https:\/\/doi.org\/10.1111\/bjh.13403.","journal-title":"Br J Haematol"},{"issue":"18","key":"862_CR23","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","volume":"24","author":"MS Davids","year":"2018","unstructured":"Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24(18):4371\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3761.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"862_CR24","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1200\/jco.2017.76.6840","volume":"36","author":"S Stilgenbauer","year":"2018","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973\u201380. https:\/\/doi.org\/10.1200\/jco.2017.76.6840.","journal-title":"J Clin Oncol"},{"issue":"3","key":"862_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, et al. Long-term efficacy and safety of first- line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787\u201398. https:\/\/doi.org\/10.1038\/s41375-019-0602-x.","journal-title":"Leukemia."},{"issue":"6","key":"862_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","volume":"32","author":"BW Teh","year":"2018","unstructured":"Teh BW, Tam CS, Handunnetti S, Worth LJ, Slavin MA. Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies. Blood Rev. 2018;32(6):499\u2013507. https:\/\/doi.org\/10.1016\/j.blre.2018.04.007.","journal-title":"Blood Rev"},{"issue":"1","key":"862_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/hematology.2020000086","volume":"2020","author":"C Moreno","year":"2020","unstructured":"Moreno C. Standard treatment approaches for relapsed\/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. Hematology Am Soc Hematol Educ Program. 2020;2020(1):33\u201340. https:\/\/doi.org\/10.1182\/hematology.2020000086.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"862_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314. https:\/\/doi.org\/10.1016\/j.jval.2013.08.2291.","journal-title":"Value Health"},{"issue":"suppl 1","key":"862_CR29","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1182\/blood-2019-123706","volume":"134","author":"MS Davids","year":"2019","unstructured":"Davids MS, Chatterjee A, Ravelo A, Shapouri S, Manzoor BS, Sail K, et al. Cost-effectiveness of a 12-month fixed duration of venetoclax in combination with obinutuzumab in first-line chronic lymphocytic leukemia in the United States. Blood. 2019;134(suppl 1):4741. https:\/\/doi.org\/10.1182\/blood-2019-123706.","journal-title":"Blood."},{"key":"862_CR30","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s40273-020-00919-1","volume":"38","author":"SK Cho","year":"2020","unstructured":"Cho SK, Manzoor BS, Sail KR, Paris\u00e9 H, Ravelo A, Shapouri S, et al. Budget impact of 12-month fixed treatment duration venetoclax in combination with obinutuzumab in previously untreated chronic lymphocytic leukemia patients in the United States. PharmacoEconomics. 2020;38:941\u201351. https:\/\/doi.org\/10.1007\/s40273-020-00919-1.","journal-title":"PharmacoEconomics."},{"issue":"30","key":"862_CR31","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.19.00894","volume":"37","author":"P Hillmen","year":"2019","unstructured":"Hillmen P, Rawstron AC, Brock K, Mu\u00f1oz-Vicente S, Yates FJ, Bishop R, et al. Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37(30):2722\u20139. https:\/\/doi.org\/10.1200\/JCO.19.00894.","journal-title":"J Clin Oncol"},{"key":"862_CR32","doi-asserted-by":"publisher","unstructured":"Tam CS, Siddiqi T, Allan JN, et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): results from the MRD cohort of the phase 2 CAPTIVATE study. Blood. 2019;134, 35(Supplement_1). https:\/\/doi.org\/10.1182\/blood-2019-121424.","DOI":"10.1182\/blood-2019-121424"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00862-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-021-00862-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00862-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T14:36:31Z","timestamp":1625582191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-021-00862-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["862"],"URL":"https:\/\/doi.org\/10.1007\/s11864-021-00862-z","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"30 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has any potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"66"}}